Comprehensive Management of Renal Masses in Solitary Kidneys.


Journal

European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904

Informations de publication

Date de publication:
02 2023
Historique:
received: 14 06 2022
revised: 20 10 2022
accepted: 20 11 2022
pubmed: 15 12 2022
medline: 11 2 2023
entrez: 14 12 2022
Statut: ppublish

Résumé

A renal mass in a solitary kidney (RMSK) has traditionally been managed with partial nephrectomy (PN), although radical nephrectomy (RN) is occasionally required. Most RMSK studies have focused on patients for whom PN was achieved. To provide a comprehensive analysis of the management strategies/outcomes for an RMSK and address knowledge deficits regarding this challenging disorder. A total of 1024 patients diagnosed with an RMSK (1975-2022) were retrospectively evaluated. Baseline characteristics and pathologic/functional/survival outcomes were analyzed. PN/RN/cryoablation (CA)/active surveillance (AS). Functional outcomes, perioperative morbidity/mortality, and 5-yr recurrence-free survival (RFS) were evaluated. Kruskal-Wallis and chi-square tests were used to compare cohorts, and log-rank test and Cox proportional hazard model were used for survival analysis. Of 1024 patients, 842 underwent PN (82%), 102 CA (10%), 54 RN (5%), and 26 AS (3%). The median tumor size and RENAL([R]adius [tumor size as maximal diameter], [E]xophytic/endophytic properties of tumor, [N]earness of tumor deepest portion to collecting system or sinus, [A]nterior [a]/posterior [p] descriptor, and [L]ocation relative to polar lines) score were 3.7 cm and 8, respectively. The median follow-up was 53 mo. For PN, 95% were clamped, and the median warm and cold ischemia times were 22 and 45 min, respectively. For PN, the median preoperative glomerular filtration rate (GFR) was 57 ml/min/1.73 m Nephron-sparing approaches are feasible and successful in most RMSK patients. PN for an RMSK is often challenging but can be facilitated by selective use of TKIs. RN is occasionally required due to severe CKD, over-riding oncologic concerns, or conversion from PN. This is the first large RMSK study to provide a comprehensive analysis of all management strategies/outcomes. Kidney cancer in a solitary kidney is a major challenge for achieving cancer-free status and avoiding dialysis. Although partial nephrectomy is the principal treatment for a renal mass in a solitary kidney, other options are occasionally required to optimize outcomes.

Sections du résumé

BACKGROUND
A renal mass in a solitary kidney (RMSK) has traditionally been managed with partial nephrectomy (PN), although radical nephrectomy (RN) is occasionally required. Most RMSK studies have focused on patients for whom PN was achieved.
OBJECTIVE
To provide a comprehensive analysis of the management strategies/outcomes for an RMSK and address knowledge deficits regarding this challenging disorder.
DESIGN, SETTING, AND PARTICIPANTS
A total of 1024 patients diagnosed with an RMSK (1975-2022) were retrospectively evaluated. Baseline characteristics and pathologic/functional/survival outcomes were analyzed.
INTERVENTION
PN/RN/cryoablation (CA)/active surveillance (AS).
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
Functional outcomes, perioperative morbidity/mortality, and 5-yr recurrence-free survival (RFS) were evaluated. Kruskal-Wallis and chi-square tests were used to compare cohorts, and log-rank test and Cox proportional hazard model were used for survival analysis.
RESULTS AND LIMITATIONS
Of 1024 patients, 842 underwent PN (82%), 102 CA (10%), 54 RN (5%), and 26 AS (3%). The median tumor size and RENAL([R]adius [tumor size as maximal diameter], [E]xophytic/endophytic properties of tumor, [N]earness of tumor deepest portion to collecting system or sinus, [A]nterior [a]/posterior [p] descriptor, and [L]ocation relative to polar lines) score were 3.7 cm and 8, respectively. The median follow-up was 53 mo. For PN, 95% were clamped, and the median warm and cold ischemia times were 22 and 45 min, respectively. For PN, the median preoperative glomerular filtration rate (GFR) was 57 ml/min/1.73 m
CONCLUSIONS
Nephron-sparing approaches are feasible and successful in most RMSK patients. PN for an RMSK is often challenging but can be facilitated by selective use of TKIs. RN is occasionally required due to severe CKD, over-riding oncologic concerns, or conversion from PN. This is the first large RMSK study to provide a comprehensive analysis of all management strategies/outcomes.
PATIENT SUMMARY
Kidney cancer in a solitary kidney is a major challenge for achieving cancer-free status and avoiding dialysis. Although partial nephrectomy is the principal treatment for a renal mass in a solitary kidney, other options are occasionally required to optimize outcomes.

Identifiants

pubmed: 36517406
pii: S2588-9311(22)00201-2
doi: 10.1016/j.euo.2022.11.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

84-94

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Yosuke Yasuda (Y)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Tokyo Medical and Dental University, Graduate School, Tokyo, Japan.

Jj H Zhang (JH)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Institute of Urologic Oncology, Department of Urology, University of California Los Angeles (UCLA), Los Angeles, CA, USA.

Worapat Attawettayanon (W)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Division of Urology, Department of Surgery, Faculty of Medicine, Songklanagarind Hospital, Prince of Songkla University, Songkhla, Thailand.

Nityam Rathi (N)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Lamont Wilkins (L)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Gustavo Roversi (G)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Ao Zhang (A)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Joao Pedro Emrich Accioly (JPE)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Snehi Shah (S)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Carlos Munoz-Lopez (C)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Diego Aguilar Palacios (DA)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Martin Hofmann (M)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Rebecca A Campbell (RA)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Jihad Kaouk (J)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Georges-Pascal Haber (GP)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Mohamad Eltemamy (M)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Venkatesh Krishnamurthi (V)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Robert Abouassaly (R)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Charles Martin (C)

Interventional Radiology, Cleveland Clinic, Cleveland, OH, USA.

Jianbo Li (J)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.

Christopher Weight (C)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Steven C Campbell (SC)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: campbes3@ccf.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH